FDA Clearance Tracker · P240021-S001
Atellica IM Total PSA II (tPSAII)
Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Aug 26, 2026
Approved
Time to decision
180 days
Received Feb 27, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P240021-S001
- Device name
- Atellica IM Total PSA II (tPSAII)
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Applicant location
- Tarrytown, NY
- Received
- Feb 27, 2026
- Decided
- Aug 26, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P240021
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the Atellica IM total PSA II (tPSAII):The Atellica IM total PSA II (tPSAII) assay is for in vitro diagnostic use in the quantitative measurement of total prostate-specific antigen (PSA) in human serum and plasma (EDTA and lithium-heparin) using the Atellica CI Analyzer. This assay is indicated as an aid in the detection of prostate cancer in conjunction with a digital rectal exam (DRE) in men aged 50 years and older. A prostate biopsy is required for the diagnosis of prostate cancer.
Source documents
Other decisions for Siemens Healthcare Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260674 · Decided Nov 6, 2026 · 249 days after receipt
Device type: System, Test, Vitamin D (MRG) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.